Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1995-10-25
1997-05-06
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514575, 514913, A61K 31215, A61K 3119
Patent
active
056272090
ABSTRACT:
9-Haloprostaglandins are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.
REFERENCES:
patent: 5004752 (1991-04-01), Raduechel et al.
patent: 5093329 (1992-03-01), Woodward
Braun, et al., "Effect of ZK 110.841 on Cerebral Vascular Contraction and TXA.sub.2 -Release Caused by Thrombin-Stimulated Platelets," Archives of Pharmacology, 339 Suppl:R37(148) (1989).
Ney, "Potent Inhibition of FMLP-Induced Neutrophil Activation by the PGD.sub.2 Analogue ZK 110.841," Archives of Pharmacology, 339 Suppl:R38(150) (1989).
"New Research Drug DLO/8149" Drug License Opportunities (IMSWORLD Publications) (Jun. 25, 1990).
Nakajima et al., Graefe's Arch. Clin. Exp. Ophthalmol., 229:411-413 (1991).
Crawford et al., J. Glaucoma, 1:94-99 (1992).
Woodward et al., Invest. Ophthalmol. Vis. Sci., 31:138-146 (1990).
Goh, et al., Graefe's Arch. Clin. Exp. Ophthalmol., 227:476-481 (1989).
Goh, et al. Jpn. J. Ophthalmol., 32:471-480 (1988).
DeSantis, Jr. Louis
Sallee Verney L.
Alcon Laboratories Inc.
Arno James A.
Copeland Barry L.
Fay Zohreh
LandOfFree
Use of certain 9-haloprostaglandins to treat glaucoma and ocular does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of certain 9-haloprostaglandins to treat glaucoma and ocular, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of certain 9-haloprostaglandins to treat glaucoma and ocular will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2133048